Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The record presents details of the completed Phase I/II study of nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for extensive-stage small cell lung cancer, including its design, eligibility, locations, and outcome measures. It also includes posted results and study documents.
    Difference
    66%
    Check dated 2026-11-08T05:15:56.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the study record remains inaccessible with a 403 Forbidden message.
    Difference
    0.2%
    Check dated 2026-11-01T02:03:42.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A banner announces updates to NIH websites and says that, during the transition, NIH content may use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI).
    Difference
    1%
    Check dated 2026-10-25T02:05:45.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-18T01:53:16.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer’s site revision number changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-11T02:23:02.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, indicating the content is blocked or unavailable rather than showing the study details. This reflects an access restriction rather than a substantive change to the study data.
    Difference
    21%
    Check dated 2026-09-20T01:04:57.000Z thumbnail image

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.